Screener
Agios Pharmaceuticals AGIO Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued expenses | 34,647 | 45,459 |
| Operating lease liabilities | 19,225 | 18,392 |
| Total current liabilities | 70,217 | 82,206 |
| Operating lease liabilities, net of current portion | 11,946 | 21,815 |
| Other non-current liabilities | 240 | 90 |
| Total liabilities | 82,403 | 104,111 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at June 30, 2026 and December 31, 2025 | — | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's operating lease liabilities?
- Agios Pharmaceuticals (AGIO) reported operating lease liabilities of $11.95M in Q2 2026.
- How has Agios Pharmaceuticals's operating lease liabilities changed year-over-year?
- Agios Pharmaceuticals's operating lease liabilities decreased by 61.7% year-over-year, from $31.17M to $11.95M.
- What is the long-term trend for Agios Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's operating lease liabilities has grown at a -25.9% compound annual growth rate (CAGR), from $97.46M to $21.82M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Agios Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude